|
|
 Previous Article | Table of Contents | Next Article 
Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a
Southwest Oncology Group Study [see comments]
BG Durie, D Stock-Novack, SE Salmon, P Finley, J Beckord, J Crowley and CA Coltman
Department of Medicine, University of Arizona, Tucson.
Six hundred twelve eligible, previously untreated patients with active
multiple myeloma and at least some data available for analysis were entered
into a randomized trial (Southwest Oncology Group [SWOG] Phase III myeloma
study 8229/30), in which the prognostic significance of pretreatment serum
beta 2 microglobulin levels was evaluated. Because there was no
statistically significant survival difference between the alternating and
syncopating VMCP/VBAP regimens, it was possible to evaluate serum beta 2
microglobulin for the total population all together. The serum beta 2
microglobulin measurements showed the highest significance of any
prognostic factor, both in the bivariate and multivariate regression
analyses. The median survival was 36 months for the 322 patients with
pretreatment serum beta 2 microglobulin values of less than 6
micrograms/mL, as compared with a median survival of 23 months for the 225
patients with a beta 2 level of greater than or equal to 6 mcg/mL (P less
than .0001). The stepwise multiple regression model first contained serum
beta 2 microglobulin, followed by serum albumin, serum calcium, age, and
serum creatinine. Serum beta 2 microglobulin was highly correlated with
stage: median values ranged from 3.7 micrograms/mL for stage IA, to 10.1
for stage IIIB. It was possible to stratify myeloma patients based on
combinations of serum beta 2 microglobulin with both albumin and age,
producing excellent separation of patients into low-, intermediate-, and
high-risk categories. It is concluded that serum beta 2 microglobulin is
the most powerful prognostic factor currently available for multiple
myeloma and that it can be used alone or in combination with other
variables for pretreatment stratification.
Volume 75,
Issue 4,
pp. 823-830,
02/15/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A.-M. Tsimberidou, H. M. Kantarjian, S. Wen, S. O'Brien, J. Cortes, W. G. Wierda, C. Koller, S. Pierce, M. Brandt, E. J. Freireich, et al.
The Prognostic Significance of Serum {beta}2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients
Clin. Cancer Res.,
February 1, 2008;
14(3):
721 - 730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Jenner, P. E. Leone, B. A. Walker, F. M. Ross, D. C. Johnson, D. Gonzalez, L. Chiecchio, E. Dachs Cabanas, G. Paolo Dagrada, M. Nightingale, et al.
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma
Blood,
November 1, 2007;
110(9):
3291 - 3300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Mulligan, C. Mitsiades, B. Bryant, F. Zhan, W. J. Chng, S. Roels, E. Koenig, A. Fergus, Y. Huang, P. Richardson, et al.
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
Blood,
April 15, 2007;
109(8):
3177 - 3188.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. R. Greipp, J. S. Miguel, B. G.M. Durie, J. J. Crowley, B. Barlogie, J. Blade, M. Boccadoro, J. A. Child, H. Avet-Loiseau, R. A. Kyle, et al.
International Staging System for Multiple Myeloma
J. Clin. Oncol.,
May 20, 2005;
23(15):
3412 - 3420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. C. Angtuaco, A. B. T. Fassas, R. Walker, R. Sethi, and B. Barlogie
Multiple Myeloma: Clinical Review and Diagnostic Imaging
Radiology,
April 1, 2004;
231(1):
11 - 23.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Onida, H. M. Kantarjian, T. L. Smith, G. Ball, M. J. Keating, E. H. Estey, A. B. Glassman, M. Albitar, M. I. Kwari, and M. Beran
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients
Blood,
February 1, 2002;
99(3):
840 - 849.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Facon, H. Avet-Loiseau, G. Guillerm, P. Moreau, F. Genevieve, M. Zandecki, J.-L. Lai, X. Leleu, J.-P. Jouet, F. Bauters, et al.
Chromosome 13 abnormalities identified by FISH analysis and serum {beta}2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy
Blood,
March 15, 2001;
97(6):
1566 - 1571.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Seidel, A. Sundan, M. Hjorth, I. Turesson, I. M. S. Dahl, N. Abildgaard, A. Waage, and M. Borset
Serum syndecan-1: a new independent prognostic marker in multiple myeloma
Blood,
January 15, 2000;
95(2):
388 - 392.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Rodriguez, J. Cortes, M. Talpaz, S. O’Brien, T. L. Smith, M. B. Rios, and H. Kantarjian
Serum {beta}-2 Microglobulin Levels Are a Significant Prognostic Factor in Philadelphia Chromosome-positive Chronic Myelogenous Leukemia
Clin. Cancer Res.,
January 1, 2000;
6(1):
147 - 152.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. Nicolaides, S. Dimou, and N. Pavlidis
Prognostic Factors in Aggressive Non-Hodgkin's Lymphomas
Oncologist,
June 1, 1998;
3(3):
189 - 197.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. Seidel, M. Borset, I. Turesson, N. Abildgaard, A. Sundan, and A. W. f. t. e Nordic Myeloma Study Group
Elevated Serum Concentrations of Hepatocyte Growth Factor in Patients With Multiple Myeloma
Blood,
February 1, 1998;
91(3):
806 - 812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.G.P. Raaijmakers, M.A.I. Izquierdo, H.M. Lokhorst, C. de Leeuw, J.A.M. Belien, A.C. Bloem, A.W. Dekker, R.J. Scheper, and P. Sonneveld
Lung-Resistance-Related Protein Expression Is a Negative Predictive Factor for Response to Conventional Low but not to Intensified Dose Alkylating Chemotherapy in Multiple Myeloma
Blood,
February 1, 1998;
91(3):
1029 - 1036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
